Gilead Acquires CAR-T Oncology Specialist Kite for US$11.9 B
By Daniel Roberts
Pharma Deals Review: Vol 2017 Issue 8 (Table of Contents)
Published: 31 Aug-2017
DOI: 10.3833/pdr.v2017.i8.2270 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Under intense shareholder pressure to do a deal and in an attempt to replace declining sales from its hepatitis C (HCV) franchise, Gilead agreed to acquire Kite Pharma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS